| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 26 | 2015 | 2831 | 1.510 |
Why?
|
| Neoplasms | 21 | 2023 | 2794 | 1.400 |
Why?
|
| Neoplasm Metastasis | 19 | 2016 | 1049 | 1.170 |
Why?
|
| Prostatic Neoplasms | 9 | 2007 | 1592 | 0.770 |
Why?
|
| Radiotherapy | 6 | 2014 | 326 | 0.740 |
Why?
|
| Epigenesis, Genetic | 1 | 2023 | 447 | 0.720 |
Why?
|
| Antineoplastic Agents | 8 | 2015 | 2324 | 0.530 |
Why?
|
| Knowledge | 1 | 2014 | 29 | 0.520 |
Why?
|
| Neovascularization, Pathologic | 6 | 2004 | 338 | 0.500 |
Why?
|
| Education, Medical | 2 | 2014 | 229 | 0.490 |
Why?
|
| Models, Theoretical | 3 | 2005 | 482 | 0.470 |
Why?
|
| Physicians, Primary Care | 1 | 2014 | 103 | 0.460 |
Why?
|
| Humans | 72 | 2023 | 83873 | 0.440 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2004 | 825 | 0.440 |
Why?
|
| Lymphatic Metastasis | 8 | 2003 | 479 | 0.440 |
Why?
|
| Physician-Patient Relations | 4 | 2007 | 602 | 0.420 |
Why?
|
| Radiation, Ionizing | 4 | 2010 | 120 | 0.400 |
Why?
|
| Radiation Oncology | 3 | 1997 | 124 | 0.380 |
Why?
|
| Human Experimentation | 1 | 2010 | 39 | 0.370 |
Why?
|
| Nucleoside-Diphosphate Kinase | 2 | 2000 | 11 | 0.360 |
Why?
|
| Ethics, Research | 1 | 2010 | 52 | 0.360 |
Why?
|
| Monomeric GTP-Binding Proteins | 2 | 2000 | 18 | 0.360 |
Why?
|
| Disease-Free Survival | 12 | 2011 | 1203 | 0.360 |
Why?
|
| Patient Advocacy | 3 | 2015 | 49 | 0.350 |
Why?
|
| MicroRNAs | 4 | 2015 | 523 | 0.340 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2005 | 461 | 0.330 |
Why?
|
| Genetic Therapy | 9 | 2008 | 340 | 0.330 |
Why?
|
| Physician's Role | 4 | 2005 | 179 | 0.320 |
Why?
|
| Models, Economic | 1 | 2007 | 60 | 0.310 |
Why?
|
| Hematopoiesis | 1 | 2008 | 164 | 0.310 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2005 | 1257 | 0.300 |
Why?
|
| Liver Neoplasms | 3 | 2018 | 680 | 0.300 |
Why?
|
| Neoplastic Stem Cells | 1 | 2008 | 142 | 0.290 |
Why?
|
| Prostatectomy | 3 | 2007 | 443 | 0.290 |
Why?
|
| Decision Making | 3 | 2007 | 631 | 0.290 |
Why?
|
| Tumor Necrosis Factor-alpha | 7 | 2008 | 673 | 0.290 |
Why?
|
| Androgen Antagonists | 2 | 2005 | 137 | 0.280 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2008 | 292 | 0.280 |
Why?
|
| Prognosis | 11 | 2005 | 3618 | 0.280 |
Why?
|
| Transcription Factors | 6 | 2004 | 1492 | 0.280 |
Why?
|
| Attitude of Health Personnel | 2 | 2005 | 633 | 0.270 |
Why?
|
| Colorectal Neoplasms | 3 | 2018 | 911 | 0.270 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2003 | 148 | 0.270 |
Why?
|
| Prostate-Specific Antigen | 2 | 1998 | 328 | 0.270 |
Why?
|
| Ethics, Medical | 3 | 2000 | 302 | 0.260 |
Why?
|
| Attitude to Health | 1 | 2005 | 220 | 0.250 |
Why?
|
| Nitriles | 1 | 2004 | 143 | 0.240 |
Why?
|
| Triazoles | 1 | 2004 | 96 | 0.240 |
Why?
|
| Biomedical Research | 3 | 2014 | 366 | 0.240 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2023 | 68 | 0.240 |
Why?
|
| History, 20th Century | 3 | 2010 | 312 | 0.230 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2003 | 59 | 0.230 |
Why?
|
| Managed Care Programs | 2 | 2000 | 42 | 0.220 |
Why?
|
| Brachytherapy | 1 | 2003 | 121 | 0.220 |
Why?
|
| Melanoma | 2 | 2013 | 443 | 0.210 |
Why?
|
| Proliferating Cell Nuclear Antigen | 2 | 2000 | 65 | 0.210 |
Why?
|
| Disease Progression | 8 | 2012 | 1478 | 0.210 |
Why?
|
| Lymph Nodes | 4 | 2000 | 527 | 0.210 |
Why?
|
| Lymph Node Excision | 1 | 2003 | 208 | 0.200 |
Why?
|
| Aged | 16 | 2018 | 18098 | 0.200 |
Why?
|
| Biomarkers, Tumor | 3 | 2003 | 1441 | 0.200 |
Why?
|
| Medical Oncology | 2 | 2014 | 347 | 0.200 |
Why?
|
| Female | 31 | 2018 | 43741 | 0.190 |
Why?
|
| Carcinoma | 1 | 2003 | 427 | 0.190 |
Why?
|
| Survival Analysis | 6 | 2013 | 1531 | 0.190 |
Why?
|
| Combined Modality Therapy | 9 | 2005 | 1645 | 0.190 |
Why?
|
| Skin Neoplasms | 1 | 2004 | 524 | 0.180 |
Why?
|
| Clinical Trials as Topic | 4 | 2014 | 1155 | 0.180 |
Why?
|
| Cadherins | 1 | 2000 | 149 | 0.180 |
Why?
|
| Middle Aged | 16 | 2018 | 24691 | 0.180 |
Why?
|
| Radiosurgery | 2 | 2013 | 272 | 0.170 |
Why?
|
| Mammography | 2 | 2000 | 457 | 0.170 |
Why?
|
| Radiotherapy, Adjuvant | 4 | 2005 | 291 | 0.160 |
Why?
|
| Gene Amplification | 1 | 2018 | 131 | 0.160 |
Why?
|
| History, 21st Century | 2 | 2009 | 175 | 0.150 |
Why?
|
| Immediate-Early Proteins | 4 | 2004 | 164 | 0.150 |
Why?
|
| Mastectomy | 2 | 2004 | 231 | 0.150 |
Why?
|
| Quality of Health Care | 1 | 2000 | 375 | 0.150 |
Why?
|
| Antigens, Neoplasm | 1 | 1998 | 319 | 0.150 |
Why?
|
| Prescription Fees | 1 | 2015 | 10 | 0.140 |
Why?
|
| Disease Models, Animal | 4 | 2016 | 2186 | 0.140 |
Why?
|
| Insurance Coverage | 1 | 1996 | 107 | 0.140 |
Why?
|
| Consumer Advocacy | 1 | 1995 | 10 | 0.140 |
Why?
|
| United States | 7 | 2015 | 6425 | 0.140 |
Why?
|
| Health Care Rationing | 1 | 1996 | 79 | 0.140 |
Why?
|
| Microcirculation | 3 | 2000 | 103 | 0.140 |
Why?
|
| Aged, 80 and over | 7 | 2018 | 6453 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2015 | 49 | 0.130 |
Why?
|
| Drug Costs | 1 | 2015 | 61 | 0.130 |
Why?
|
| Erectile Dysfunction | 2 | 2007 | 69 | 0.130 |
Why?
|
| Neoplasm Staging | 5 | 2004 | 1932 | 0.130 |
Why?
|
| Patients | 1 | 1995 | 98 | 0.130 |
Why?
|
| Medical Laboratory Science | 1 | 1994 | 7 | 0.130 |
Why?
|
| Radiotherapy, Computer-Assisted | 2 | 2008 | 25 | 0.130 |
Why?
|
| Clinical Medicine | 1 | 1994 | 34 | 0.120 |
Why?
|
| Aging | 1 | 1998 | 670 | 0.120 |
Why?
|
| Life Expectancy | 1 | 1994 | 82 | 0.120 |
Why?
|
| Genetic Engineering | 1 | 1994 | 112 | 0.120 |
Why?
|
| Urinary Incontinence | 2 | 2007 | 192 | 0.120 |
Why?
|
| Patient Participation | 1 | 2015 | 207 | 0.120 |
Why?
|
| Male | 13 | 2018 | 40239 | 0.120 |
Why?
|
| Adult | 12 | 2018 | 25203 | 0.110 |
Why?
|
| History, 19th Century | 2 | 2009 | 59 | 0.110 |
Why?
|
| Health Care Reform | 1 | 1994 | 90 | 0.110 |
Why?
|
| Data Interpretation, Statistical | 2 | 2004 | 296 | 0.110 |
Why?
|
| Treatment Outcome | 6 | 2013 | 7776 | 0.110 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 455 | 0.100 |
Why?
|
| Evidence-Based Medicine | 2 | 2005 | 422 | 0.100 |
Why?
|
| Animals | 15 | 2016 | 26005 | 0.100 |
Why?
|
| Informed Consent | 2 | 2010 | 259 | 0.100 |
Why?
|
| Neoplasm Transplantation | 6 | 2016 | 386 | 0.100 |
Why?
|
| Age Factors | 3 | 2007 | 1823 | 0.100 |
Why?
|
| Philosophy, Medical | 2 | 2005 | 17 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2000 | 3603 | 0.100 |
Why?
|
| Multivariate Analysis | 3 | 1998 | 988 | 0.100 |
Why?
|
| Ohio | 1 | 2010 | 36 | 0.100 |
Why?
|
| Tamoxifen | 2 | 2004 | 165 | 0.090 |
Why?
|
| Hodgkin Disease | 1 | 1991 | 173 | 0.090 |
Why?
|
| NM23 Nucleoside Diphosphate Kinases | 2 | 2000 | 5 | 0.090 |
Why?
|
| Lung | 2 | 2012 | 1124 | 0.090 |
Why?
|
| Biological Evolution | 1 | 1997 | 901 | 0.090 |
Why?
|
| Research Subjects | 1 | 2010 | 73 | 0.090 |
Why?
|
| X-Ray Therapy | 1 | 2008 | 6 | 0.090 |
Why?
|
| Universities | 1 | 2010 | 135 | 0.090 |
Why?
|
| Cell Line, Tumor | 5 | 2015 | 2380 | 0.090 |
Why?
|
| Lung Neoplasms | 3 | 2013 | 2221 | 0.090 |
Why?
|
| Analysis of Variance | 2 | 2004 | 914 | 0.090 |
Why?
|
| Military Personnel | 1 | 2010 | 79 | 0.090 |
Why?
|
| Adenocarcinoma | 3 | 2012 | 1155 | 0.080 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2008 | 96 | 0.080 |
Why?
|
| Survival Rate | 3 | 2012 | 1843 | 0.080 |
Why?
|
| Melanoma, Experimental | 1 | 2008 | 101 | 0.080 |
Why?
|
| Philosophy | 1 | 2007 | 9 | 0.080 |
Why?
|
| Radiotherapy, Conformal | 1 | 2008 | 88 | 0.080 |
Why?
|
| Urethral Stricture | 1 | 2007 | 11 | 0.080 |
Why?
|
| Rectal Diseases | 1 | 2007 | 29 | 0.080 |
Why?
|
| Critical Pathways | 1 | 2007 | 35 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 1993 | 573 | 0.080 |
Why?
|
| DNA-Binding Proteins | 4 | 2004 | 1201 | 0.080 |
Why?
|
| Mutation | 1 | 2018 | 3889 | 0.080 |
Why?
|
| Actuarial Analysis | 2 | 1997 | 66 | 0.070 |
Why?
|
| Phenotype | 3 | 2015 | 2323 | 0.070 |
Why?
|
| Time Factors | 4 | 2005 | 5176 | 0.070 |
Why?
|
| Fund Raising | 1 | 2005 | 2 | 0.070 |
Why?
|
| Academies and Institutes | 1 | 2006 | 30 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2003 | 1636 | 0.070 |
Why?
|
| Dermatology | 1 | 2006 | 35 | 0.070 |
Why?
|
| Gene Expression Regulation | 3 | 2002 | 1889 | 0.070 |
Why?
|
| Immunohistochemistry | 3 | 2000 | 1736 | 0.070 |
Why?
|
| Gene Expression Profiling | 3 | 2018 | 1355 | 0.070 |
Why?
|
| Trastuzumab | 1 | 2005 | 64 | 0.070 |
Why?
|
| Heterografts | 2 | 2015 | 98 | 0.070 |
Why?
|
| Sample Size | 1 | 2005 | 128 | 0.070 |
Why?
|
| Mastectomy, Radical | 2 | 1995 | 10 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2003 | 917 | 0.060 |
Why?
|
| Patient Satisfaction | 1 | 2007 | 457 | 0.060 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2004 | 109 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2007 | 792 | 0.060 |
Why?
|
| Doxorubicin | 1 | 2004 | 284 | 0.060 |
Why?
|
| Radiation Dosage | 2 | 2011 | 223 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2004 | 2390 | 0.060 |
Why?
|
| Carcinoma, Lewis Lung | 2 | 2000 | 22 | 0.060 |
Why?
|
| Mice | 9 | 2015 | 10930 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 1 | 2004 | 522 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2005 | 412 | 0.060 |
Why?
|
| Interdisciplinary Communication | 1 | 2003 | 127 | 0.050 |
Why?
|
| Surgical Procedures, Operative | 1 | 2004 | 184 | 0.050 |
Why?
|
| Early Growth Response Protein 1 | 4 | 2004 | 54 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 854 | 0.050 |
Why?
|
| Lymphedema | 1 | 2003 | 75 | 0.050 |
Why?
|
| Transcriptional Activation | 1 | 2002 | 276 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2003 | 1967 | 0.050 |
Why?
|
| Coumarins | 1 | 2000 | 13 | 0.050 |
Why?
|
| Risk | 1 | 2003 | 671 | 0.050 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2000 | 189 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2003 | 682 | 0.050 |
Why?
|
| Immunity, Cellular | 1 | 2001 | 175 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2005 | 2223 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 5 | 2002 | 1030 | 0.050 |
Why?
|
| Gene Expression | 2 | 2015 | 1276 | 0.050 |
Why?
|
| Cisplatin | 1 | 2002 | 600 | 0.050 |
Why?
|
| Databases as Topic | 1 | 2000 | 92 | 0.050 |
Why?
|
| Mice, Nude | 5 | 2002 | 762 | 0.050 |
Why?
|
| Cancer Vaccines | 1 | 2001 | 154 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2005 | 918 | 0.050 |
Why?
|
| Carcinoma, Lobular | 1 | 2000 | 79 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2005 | 1357 | 0.040 |
Why?
|
| Plasminogen | 1 | 1998 | 41 | 0.040 |
Why?
|
| Apoptosis | 3 | 2008 | 1667 | 0.040 |
Why?
|
| Genetic Vectors | 4 | 2004 | 434 | 0.040 |
Why?
|
| Class II Phosphatidylinositol 3-Kinases | 1 | 2018 | 8 | 0.040 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2000 | 154 | 0.040 |
Why?
|
| Research | 2 | 2003 | 252 | 0.040 |
Why?
|
| Receptor, Notch1 | 1 | 2018 | 83 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2002 | 1118 | 0.040 |
Why?
|
| Paraffin Embedding | 1 | 1997 | 78 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 1753 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2011 | 448 | 0.040 |
Why?
|
| Mutagenesis | 1 | 1997 | 199 | 0.040 |
Why?
|
| Adrenalectomy | 1 | 1996 | 41 | 0.040 |
Why?
|
| Axilla | 1 | 1997 | 93 | 0.040 |
Why?
|
| Insurance, Health | 1 | 1998 | 148 | 0.040 |
Why?
|
| Ovariectomy | 1 | 1996 | 78 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2000 | 533 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 1998 | 458 | 0.040 |
Why?
|
| HCT116 Cells | 1 | 2016 | 149 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 387 | 0.040 |
Why?
|
| Researcher-Subject Relations | 1 | 1996 | 4 | 0.040 |
Why?
|
| Molecular Biology | 1 | 1996 | 88 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2001 | 595 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2004 | 1055 | 0.040 |
Why?
|
| Social Responsibility | 1 | 1996 | 57 | 0.030 |
Why?
|
| Fibrosarcoma | 1 | 1995 | 86 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 2015 | 57 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 1997 | 573 | 0.030 |
Why?
|
| DNA Repair | 1 | 1997 | 352 | 0.030 |
Why?
|
| Laryngeal Neoplasms | 1 | 1995 | 89 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 1996 | 192 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2015 | 181 | 0.030 |
Why?
|
| Algorithms | 1 | 2003 | 1803 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2015 | 237 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 1995 | 253 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 1996 | 852 | 0.030 |
Why?
|
| Research Design | 2 | 2003 | 581 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2015 | 278 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 1995 | 270 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 1996 | 550 | 0.030 |
Why?
|
| Social Values | 1 | 1994 | 44 | 0.030 |
Why?
|
| Regression Analysis | 1 | 1995 | 596 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 1994 | 71 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 1995 | 376 | 0.030 |
Why?
|
| Genetic Diseases, Inborn | 1 | 1994 | 100 | 0.030 |
Why?
|
| Health Care Costs | 1 | 1995 | 230 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 1995 | 197 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 568 | 0.030 |
Why?
|
| Forecasting | 1 | 1994 | 309 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 264 | 0.030 |
Why?
|
| Adenoviridae | 2 | 2004 | 344 | 0.030 |
Why?
|
| Social Change | 1 | 1991 | 7 | 0.030 |
Why?
|
| England | 1 | 1991 | 42 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1991 | 77 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2011 | 270 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2011 | 362 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 1991 | 150 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2011 | 255 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2014 | 378 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 2 | 2004 | 922 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1996 | 1065 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2008 | 20 | 0.020 |
Why?
|
| Etanercept | 1 | 2008 | 32 | 0.020 |
Why?
|
| Esophageal Neoplasms | 2 | 2002 | 316 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2008 | 43 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2008 | 87 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 1993 | 504 | 0.020 |
Why?
|
| Rats | 2 | 2004 | 3941 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 1991 | 1797 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 1991 | 374 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2008 | 447 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2000 | 8061 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 1181 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2008 | 404 | 0.020 |
Why?
|
| Necrosis | 2 | 1996 | 191 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 2652 | 0.020 |
Why?
|
| Pleural Effusion | 1 | 2004 | 44 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2004 | 94 | 0.020 |
Why?
|
| Acetylcysteine | 1 | 2004 | 69 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 2 | 1996 | 550 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 231 | 0.020 |
Why?
|
| Genes, erbB-2 | 1 | 2003 | 24 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 351 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 967 | 0.010 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2003 | 31 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 2000 | 3025 | 0.010 |
Why?
|
| Receptors, Steroid | 1 | 2003 | 42 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2004 | 458 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 391 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2004 | 698 | 0.010 |
Why?
|
| Phytotherapy | 1 | 2003 | 132 | 0.010 |
Why?
|
| Isocoumarins | 1 | 2000 | 7 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 2000 | 45 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2004 | 580 | 0.010 |
Why?
|
| Laminin | 1 | 2000 | 81 | 0.010 |
Why?
|
| ROC Curve | 1 | 2003 | 743 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2000 | 218 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2000 | 118 | 0.010 |
Why?
|
| Mass Screening | 1 | 2004 | 609 | 0.010 |
Why?
|
| Collagen | 1 | 2000 | 266 | 0.010 |
Why?
|
| Angiostatins | 1 | 1998 | 16 | 0.010 |
Why?
|
| Cytokines | 1 | 2003 | 754 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2000 | 429 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2002 | 550 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2004 | 2703 | 0.010 |
Why?
|
| Cell Movement | 1 | 2000 | 737 | 0.010 |
Why?
|
| Biomarkers | 1 | 2003 | 1654 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2000 | 1948 | 0.010 |
Why?
|
| Mastadenovirus | 1 | 1995 | 4 | 0.010 |
Why?
|
| Liposomes | 1 | 1995 | 92 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2000 | 2763 | 0.010 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1995 | 108 | 0.010 |
Why?
|
| Radiation Tolerance | 1 | 1995 | 168 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 1995 | 349 | 0.010 |
Why?
|
| Thrombosis | 1 | 1996 | 284 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2003 | 3179 | 0.010 |
Why?
|